Manoussos Perros
Vorstandsvorsitzender bei ENTASIS THERAPEUTICS HOLDINGS INC.
Aktive Positionen von Manoussos Perros
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ENTASIS THERAPEUTICS HOLDINGS INC. | Direktor/Vorstandsmitglied | 01.05.2015 | - |
Vorstandsvorsitzender | 01.05.2015 | - | |
Präsident | 01.05.2015 | - | |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Direktor/Vorstandsmitglied | 01.05.2015 | - |
Vorstandsvorsitzender | 01.05.2015 | - | |
Gründer | 01.05.2015 | - | |
Präsident | 01.05.2015 | - | |
Entasis Therapeutics Ltd.
Entasis Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Part of Innoviva, Inc., Entasis Therapeutics Ltd. is a British pharmaceutical company founded in 2015. The company is based in Altrincham, UK and manufactures and distributes pharmaceutical products. | Direktor/Vorstandsmitglied | 11.05.2015 | - |
Karriereverlauf von Manoussos Perros
Ehemalige bekannte Positionen von Manoussos Perros
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | 01.01.2010 | 01.01.2015 |
Yale University | Corporate Officer/Principal | 01.01.1993 | 01.01.1995 |
PFIZER, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Novartis Institute for Tropical Diseases Pte Ltd.
Novartis Institute for Tropical Diseases Pte Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Institute for Tropical Diseases Pte Ltd. is a Singaporean company that develops novel small molecule therapies for tropical infectious diseases. The company is based in Singapore, Singapore. | Direktor/Vorstandsmitglied | - | - |
Statistik
International
Vereinigte Staaten | 5 |
Schweden | 2 |
Singapur | 2 |
Operativ
Director/Board Member | 4 |
Chief Executive Officer | 2 |
President | 2 |
Sektoral
Health Technology | 6 |
Commercial Services | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
PFIZER, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Entasis Therapeutics Holdings, Inc.
Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Novartis Institute for Tropical Diseases Pte Ltd.
Novartis Institute for Tropical Diseases Pte Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Institute for Tropical Diseases Pte Ltd. is a Singaporean company that develops novel small molecule therapies for tropical infectious diseases. The company is based in Singapore, Singapore. | Health Technology |
Entasis Therapeutics Ltd.
Entasis Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Part of Innoviva, Inc., Entasis Therapeutics Ltd. is a British pharmaceutical company founded in 2015. The company is based in Altrincham, UK and manufactures and distributes pharmaceutical products. | Health Technology |
- Börse
- Insiders
- Manoussos Perros
- Erfahrung